APA (7th ed.) Citation

F, V., L, V. D., A, V. D., K, P., U, R., J, S., & J, V. (2021). CGRP monoclonal antibodies in migraine: An efficacy and tolerability comparison with standard prophylactic drugs. The journal of headache and pain, 22(1), 128. https://doi.org/10.1186/s10194-021-01335-2

Chicago Style (17th ed.) Citation

F, Vandervorst, Van Deun L, Van Dycke A, Paemeleire K, Reuter U, Schoenen J, and Versijpt J. "CGRP Monoclonal Antibodies in Migraine: An Efficacy and Tolerability Comparison with Standard Prophylactic Drugs." The Journal of Headache and Pain 22, no. 1 (2021): 128. https://doi.org/10.1186/s10194-021-01335-2.

MLA (9th ed.) Citation

F, Vandervorst, et al. "CGRP Monoclonal Antibodies in Migraine: An Efficacy and Tolerability Comparison with Standard Prophylactic Drugs." The Journal of Headache and Pain, vol. 22, no. 1, 2021, p. 128, https://doi.org/10.1186/s10194-021-01335-2.